期刊文献+

西仑吉肽的合成制备 被引量:2

Synthesis and Preparation of Cilengitide
原文传递
导出
摘要 西仑吉肽(cilengitide)是一个含RGD序列人工改造设计得到的生物活性环肽,对整合素αvβ3具有较高的亲和性和选择性。本研究主要对西伦吉肽合成方法进行研究:采用固液相结合合成法,以二氯树脂为固相载体,以HBTU、PyBOP为缩合剂,固相合成线性肽后液相合成环肽,采用制备型反相高效液相色谱法进行纯化。产品纯度为98.3%,总收率为28.2%。该合成方法简单易行,产品纯度较高,适合用于西仑吉肽工业生产。 Cilengitide, a kind of bioactive cyclopeptide, is derived from the redesign of a sequence con- taining RGD and it has better affinity and selectivity for av/33. This article focused on the research of the synthesis of cilengitide : combining the solid phase synthesis of the linear precursor and solvent phase syn- thesis of the cyclopeptide. Cilengitide was synthesized successfully with the raw material of Fmoc-amino acids and 2CTC- resin as vector, HBTU and PyBOP as coupling agents, and was purified with reverse phase high performance liquid chromatography. The purity of the refined peptide after purification was 98.3% and the overall yield was 28.2%. This method is very practical and applicable to the industrial manufacture.
出处 《化学工业与工程》 CAS 2012年第4期33-37,共5页 Chemical Industry and Engineering
关键词 西仑吉肽 固相合成 液相合成 cilengitide solid phase synthesis solvent phase synthesis
  • 相关文献

参考文献11

  • 1MAS-MORUNO C,RECHENMACHER F,KESSLER H. Cilengitide :The first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation [ J ]. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10: 753 -768.
  • 2HEHLGANS S, MICHAEL H,NILS C. Signalling via integrins: Implications for cell survival and anticancer strategies [J]. Biochimica et Biophysica Acta, 2007, ( 1775 ) : 163 - 180.
  • 3KALSER E,COLESCOTT R L, BOSSING C D, et al. Color test for detection of terminal amino groups in the solid phase synthesis of peptides [ J ]. Anal Biochem,1970,34:595 -598.
  • 4张俊,杨明,王安明,王华,周成,杜志强,祝社民,沈树宝.微波作用下大位阻氨基酸与H-Pro-CTC树脂的高效缩合[J].有机化学,2008,28(12):2119-2125. 被引量:3
  • 5林浩,王德心.哌嗪二酮衍生物的合成研究进展[J].药学学报,2003,38(5):395-400. 被引量:11
  • 6唐艳春,田桂玲,叶蕴华.环肽合成方法的研究进展[J].高等学校化学学报,2000,21(7):1056-1063. 被引量:13
  • 7吴蕾,任云霞,景文鹏.神经降压素的固相合成工艺研究[J].化学工业与工程,2009,26(4):292-297. 被引量:3
  • 8SEWALD N,JAKUBKE H J. Peptides-Chemistry and biology[ M ]. Germany : Wiley-VCH ,2002.
  • 9CUPIDO T, SPENGLER J, RUIZ-RODRIGUEZ J, et al. Amide-to-ester substitution allows fine-tuning of the cy- clopeptide conformational ensemble [ J ]. Angew Chem Int Ed Engl,2010,49( 15 ) :2 732 -2 737.
  • 10CLARK R J,AKCAN M, KAAS Q,et al. Cyclization of conotoxins to improve their biopharmaceutical properties [ J/OL ]. Toxicon ( 2010 ) , doi: 10. 1016/j. toxicon. 2010 - 12 -03.

二级参考文献51

  • 1林浩,王德心.哌嗪二酮衍生物的合成研究进展[J].药学学报,2003,38(5):395-400. 被引量:11
  • 2陈向明,陈河如.芴烯—哌啶加合物的紫外光谱研究及其应用[J].中山大学学报(自然科学版),2005,44(6):61-63. 被引量:4
  • 3邹永水 钱肖贞.固相上氨基酸与多肽氨基的测定[J].生物化学与生物物理进展,1978,(4):12-12.
  • 4CARYAWAY R E,LEEMAN S E.The isolation of a new hypotensive peptide,neurotensin from bovine hypothalamus[J].Biol Chem,1973,248(19):6 854-6 861.
  • 5GULLO L,PEZZILLI R.TOMASSETTI P,et al.Plasma cholecystokinin and neurotensin after an ordinary meal in humans:A prolonged time study[J].Castmenteml Clin Bjol,1998,22(1):25-28.
  • 6COLLIER N A,WEINBREN K,BLOOM S R,et al.Neurotensin secretion by fibrolmeler caroinoma of the live[J].The Lancet,1984(1):538-540.
  • 7ZADINA J E,HACKLER L,GE L J,et al.A potent and selective endogenous agonist for the mu-opiate receptor[J].Nature,1997,386:499-501.
  • 8MAEHIDA R,TOKUMURA T,TSUEHIYA Y,et al.Pharmacokineties of novel hexapeptides with neurotensin activity in rats[J].Biol Pharm Bull,1993,16(1):43-47.
  • 9KALSER E,COLESCOTT L,BOSSING C D,et al.Color test for detection of terminal amino groups in the solid phase synthesis of peptdes[J].Anal Biochem,1970,34:595.
  • 10韩香.Fmoc方法固相合成胸腺素a1[D].天津:天津大学,2000.

共引文献22

同被引文献27

  • 1黄容琴,裴元英.基因治疗中非病毒载体的研究进展[J].国外医学(药学分册),2005,32(2):77-81. 被引量:4
  • 2张丽珺,方晓玲.聚合物纳米粒和胶束的主动靶向研究进展[J].国外医学(药学分册),2005,32(6):399-403. 被引量:6
  • 3Valverde l E, Lecaille F, Lalmanach G, et al. Synthesis of a biologically active triazole-containing analogue of cystatin A through successive peptidomimetic alkyne-azide ligations[J]. Angew Chem Int Ed Engl, 2012,51(3):718-722.
  • 4Roberts M J, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation [J]. Adv Drug Dolly Rev, 2002, 54(4): 459-476.
  • 5Bertram A, Pattenden G, Marine metabolites: metalbinding and metal complexes of azole-based eyeliepeptides of ma- rine origin[J]. Nat Prod Rep, 2007, 24(1):18-30.
  • 6Wang T, Danishefsky SJ. Solid-phase peptide synthesis and solid-phase fragment coupling mediated by isonitriles[J]. PNAS, 2013, 110(29):11708-11713.
  • 7Mishra SK, Majumdar P, Behera RK, et al. Synthesis of 3- substiiuted pyrazole derivatives by mixed anhydride method and study of their antibacterial activities[J].Tylor Francis, 2014, 44(1):32-41.
  • 8Benon NL. Peptide synthesis: coupling methods[J].Chen Infarm, 2010, 41(12):1-9.
  • 9Lewis RJ, Dutertre S, Vetter I, et al. Conus. venom peptide pharmacology[J]. Pharmacol Rev, 2012, 64(2):259-298.
  • 10Harmar A J, Fahmnkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyelase-activating polypeptide: IUPHAR review l[J]. Br J Pharmaeol, 2012, 166(1):4-17.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部